The purpose of the SPORE Tissue and Pathology Core is two-fold: 1. to provide research pathology services to SPORE investigators, including histology, immunohistochemistry, in situ hybridization, computer- assisted image analysis, digital imaging, laser capture microdissection, tissue microarrays, rodent pathology services, and immortalization of cell lines; and 2. to provide a tissue/blood repository for use by SPORE investigators, including collection, processing, and storage of blood and blood components (plasma, peripheral blood mononuclear cells, and circulating tumor cells) from patients enrolled in SPORE-related projects. In addition a virtual specimen bank will be created which will link together the extensive existing tissue resources among the Dana Farber/Harvard Cancer Center hospitals. All SPORE investigators will have access to the material in these banks. The research pathology services are essential for the evaluation of new markers, probes and antibodies developed by SPORE investigators. The tissue/blood repository will provide SPORE investigators with access to a wide range of clinical material with associated information. In this regard, there will be close collaboration between the Tissue and Pathology Core and the Clinical Database and Data Management Core which will be responsible for providing and maintaining the clinical databases for samples stored in the tissue/blood repository, linked to clinical data, behind a secure data management system that will be available to DF/HCC SPORE investigators as well as SPORE investigators at other institutions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA089393-01
Application #
6402287
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2000-09-30
Project End
2005-09-29
Budget Start
Budget End
Support Year
1
Fiscal Year
2000
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02115
Kabraji, Sheheryar; Ni, Jing; Lin, Nancy U et al. (2018) Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain? Clin Cancer Res 24:1795-1804
Punglia, Rinaa S; Jiang, Wei; Lipsitz, Stuart R et al. (2018) Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery. Breast Cancer Res Treat 167:751-759
Liu, Hui; Murphy, Charles J; Karreth, Florian A et al. (2018) Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer. Cancer Discov 8:354-369
Asdourian, Maria S; Swaroop, Meyha N; Sayegh, Hoda E et al. (2017) Association Between Precautionary Behaviors and Breast Cancer-Related Lymphedema in Patients Undergoing Bilateral Surgery. J Clin Oncol 35:3934-3941
Sherr, Charles J; Beach, David; Shapiro, Geoffrey I (2016) Targeting CDK4 and CDK6: From Discovery to Therapy. Cancer Discov 6:353-67
Asdourian, Maria S; Skolny, Melissa N; Brunelle, Cheryl et al. (2016) Precautions for breast cancer-related lymphoedema: risk from air travel, ipsilateral arm blood pressure measurements, skin puncture, extreme temperatures, and cellulitis. Lancet Oncol 17:e392-405
Kochupurakkal, Bose S; Iglehart, J Dirk (2016) Identification of genes responsible for RelA-dependent proliferation arrest in human mammary epithelial cells conditionally expressing RelA. Genom Data 7:92-3
Vaz-Luis, Ines; Hughes, Melissa E; Cronin, Angel et al. (2016) Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers. Breast Cancer Res Treat 155:569-78
Sun, Fangdi; Skolny, Melissa N; Swaroop, Meyha N et al. (2016) The need for preoperative baseline arm measurement to accurately quantify breast cancer-related lymphedema. Breast Cancer Res Treat 157:229-240
Ferguson, Chantal M; Swaroop, Meyha N; Horick, Nora et al. (2016) Impact of Ipsilateral Blood Draws, Injections, Blood Pressure Measurements, and Air Travel on the Risk of Lymphedema for Patients Treated for Breast Cancer. J Clin Oncol 34:691-8

Showing the most recent 10 out of 291 publications